AKT1 and prostate cancer: Indeed, EGCG suppresses the activation of NF-κB, PI3K/Akt, and ERK1/2 pathways and blocks AP-1 activity, thereby reducing levels of pro-inflammatory enzymes such as iNOS and COX-2 and scavenges reactive species in colon and prostate cancer cells [367–369].